Parabilis Medicines, Inc. Initiated at Buy by HC Wainwright & Co.

HC Wainwright & Co. initiated research coverage on Parabilis Medicines, Inc. (PBLS) on October 22, 2026, assigning a 'Buy' rating with a price target of $40.00 per share. This marks a positive shift in analyst sentiment regarding the company's market position and development pipeline.